Using different mouse tumor models, including allograft mouse models, GEMMs, and PDX mouse models, we provide a therapeutic strategy by combining MEK and autophagy inhibition for the treatment of LKB1-mutant KRAS-driven NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.